Merck & Co., Inc. (MRK), known as MSD outside of the U.S. and Canada, announced Monday the start of construction for a $3 billion, 400,000-square-foot pharmaceutical manufacturing facility at its Elkton, Virginia, site.
Merck's investment in the Center of Excellence for Pharmaceutical Manufacturing is part of a more than $70 billion investment beginning in 2025 to expand domestic manufacturing and research and development to drive its long-term growth. This will not include any future business development transactions in R&D.
The $3 billion expansion builds on Merck's nearly 85-year history in Elkton, Virginia, enhancing the site with a state-of-the-art pharmaceutical Center of Excellence. This will include both Active Pharmaceutical Ingredient and Drug Product investment supporting small molecule manufacturing and testing.
The investment will potentially lead to the creation of more than 500 full-time roles as well as 8,000 construction jobs.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.